Skip to Content

'
Anna R.K. Franklin, M.D.

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Pediatrics Patient Care, Division of Pediatrics, Children's Cancer Hospital at The University of Texas MD Anderson Cancer Center, Leukemia/Lymphoma Section, Houston, TX

Education & Training

Degree-Granting Education

1997 The University of Texas Medical School, Houston, TX, MD, Medicine
1992 The University of Saint Thomas, Houston, TX, BS, Biology

Postgraduate Training

7/2003-6/2004 Chief Fellow, Pediatric Hematology/Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, Paul Meyers, MD
7/2001-6/2004 Fellowship, Pediatric Hematology/Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, Paul Meyers, MD
7/1997-6/2001 Residency, Internal Medicine & Pediatrics, University of Texas Medical School, Houston, TX, Mark Farnie, MD

Board Certifications

2011 Internal Medicine
2004 Pediatric Hematology Oncology
2002 Pediatrics

Experience/Service

Academic Appointments

Instructor, Division of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, 9/2004-9/2006

Selected Publications

Peer-Reviewed Original Research Articles

1. Levy AG, Zage PE, Akers LJ, Ghisoli ML, Chen Z, Fang W, Kannan S, Graham T, Zeng L, Franklin AR, Huang P, Zweidler-McKay PA. The combination of the novel glycolysis inhibitor 3-BrOP and rapamycin is effective against neuroblastoma. Invest New Drugs 30(1):191-9, 2/2012. e-Pub 10/2010. PMID: 20890785.
2. Fanale MA, Forero-Torres A, Rosenblatt JD, Advani RH, Franklin AR, Kennedy DA, Han TH, Sievers EL, Bartlett NL. A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies. Clin Cancer Res 18(1):248-55, 1/2012. e-Pub 11/2011. PMID: 22080439.
3. Akers LJ, Fang W, Levy AG, Franklin AR, Huang P, Zweidler-McKay PA. Targeting glycolysis in leukemia: A novel inhibitor 3-BrOP in combination with rapamycin. Leuk Res 35(6):814-20, 6/2011. e-Pub 2/2011. PMID: 21316758.
4. Borsotti C, Franklin AR, Lu SX, Kim TD, Smith OM, Suh D, King CG, Chow A, Liu C, Alpdogan O, van den Brink MRM. Absence of donor T-cell-derived soluble TNF decreases graft-versus- host disease without impairing graft-versus-tumor activity. Blood 11(2). e-Pub 3/2007.
5. Giles FJ, Shi GG, Cortes JE, Thomas D, Keating AR, Kantarjian HM, Keating MJ, OBrien SM. Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia. Cancer Chemotherapy & Pharmacology 52(3):223-228, 2003. PMID: 12783199.

Editorials

1. Chinen J, Anmuth D, Franklin ARK, Shearer WT. Long term follow-up of patients with primary immunodeficiency. Journal of Allergy and Clinical Immunology 122(5):1036-7, 11/2008.

Last updated: 5/21/2014